Discussions on transcatheter aortic valve replacement (TAVR) at last week’s Transcatheter Valve Therapies (TVT) meeting in Chicago were upbeat on the prospect of landing an intermediate-risk indication later this year, despite turbulence around reports of complications and questions of long-term success.